BioScrip, Inc. (BIOS) Misses Q2 EPS by 5c, Offers Guidance
Tweet
Share
E-mailGet Alerts BIOS Hot Sheet
Price: $10.80 --0%
Financial Fact:
Cost of revenue: 161.96M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Financial Fact:
Cost of revenue: 161.96M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
BioScrip, Inc. (NASDAQ: BIOS) reported Q2 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $247.1 million versus the consensus estimate of $233.7 million.
BioScrip, Inc. sees FY2014 revenue of $940-980 million, versus the consensus of $966.20 million.
For earnings history and earnings-related data on BioScrip, Inc. (BIOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
- Textron (TXT) Misses Q1 EPS by 2c, misses on revenue; beats on guidance
- Northrop Grumman (NOC) Tops Q1 EPS by 54c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
